MedTrace Logo

Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients

NCT03560583 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-02-10

No results posted yet for this study

Summary

Poor ovarian response population of ART are considered the biggest challenge for providers. Hitherto, no one protocol has been proven to be effect in this subgroup of IVF patients.

Metoclopramide belongs to the antiemetic group, used for motion sickness and during early gestation for hyperemesis gravidarum.

The mechanism of action is antagonisim to dopamine receptors. We hypothesize than by blocking dopamine receptors and decreasing the dopaminergic tone there is a possibility to increase the sensitivity of ovarian response to gonadotropins during controlled ovarian stimulation and result in increased oocyte retrival.

Conditions

  • Poor Responders in IVF

Interventions

DRUG

Metoclopramide

Metoclopramide 10 mg BID

DRUG

Placebo Oral Tablet

Placebo 10 mg BID

Sponsors & Collaborators

  • Barzilai Medical Center

    lead OTHER

Principal Investigators

  • Leon Grin, MD · Barzilai Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
54 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-05
Primary Completion
2027-12-31
Completion
2028-07-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03560583 on ClinicalTrials.gov